<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1145">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146245</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2021-0278</org_study_id>
    <secondary_id>2020-005450-18</secondary_id>
    <nct_id>NCT05146245</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT</brief_title>
  <acronym>SPACe2:STAR</acronym>
  <official_title>Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting de Merel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test whether therapeutic drug monitoring of risperidone in&#xD;
      children with autism spectrum disorder and comorbid behavioral problems is able to reduce&#xD;
      metabolic side effect burden, while retaining clinical effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI z-score</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in body mass index z-scores 6 months after start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectivity (ABC)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference on the Irritability scale of the Aberrant Behavior Checklist (scores ranging from 0 to 45, a higher score means more symptoms) 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectivity (CGI)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference on the Clinical Global Impression scale (scores ranging from 1 to 7, a higher score means higher severity) 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (PedsQL)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference on Pediatric Quality of Life Inventory (scores ranging from 0 to 100, a higher score indicates a better quality of life) 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic side effects (glucose)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in level of glucose 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic side effects (cholesterol)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in levels of cholesterol and lipoproteins (LDL, HDL) 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic side effects (triglycerides)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in level of triglycerides 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine side effects (prolactin)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in level of prolactin 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrapyramidal symptoms (EPS)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in extrapyramidal symptoms measured by Abnormal Involuntary Movement Scale 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine side effects (ghrelin)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in level of ghrelin 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine side effects (leptin)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in level of leptin 6 months after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects (blood pressure)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in diastolic and systolic blood pressure 6 months after start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Therapeutic Drug Monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physicians receive dosing advice based on measured blood levels of risperidone and 9-OH-risperidone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Care As Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physician decides on possible dosing changes without receiving advice based on blood levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic Drug Monitoring</intervention_name>
    <description>Physician receives dosing advice based on risperidone plasma level.</description>
    <arm_group_label>Therapeutic Drug Monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Risperidone plasma level</intervention_name>
    <description>Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.</description>
    <arm_group_label>Care As Usual</arm_group_label>
    <arm_group_label>Therapeutic Drug Monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 to 18 years&#xD;
&#xD;
          -  Documented clinical diagnosis of autism spectrum disorder according to DSM IV or DSM V&#xD;
             and comorbid behavioural problems&#xD;
&#xD;
          -  To start treatment with risperidone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes type I or II&#xD;
&#xD;
          -  Congenital or acquired syndrome associated with changes in appetite, body weight or&#xD;
             lipid profile (e.g. Prader Willi)&#xD;
&#xD;
          -  Treatment with antipsychotic medication within the last 6 months&#xD;
&#xD;
          -  Known Long QT syndrome (LQTS)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Birgit Koch</last_name>
    <email>b.koch@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hermans</last_name>
      <email>SPACe@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Birgit Koch</investigator_full_name>
    <investigator_title>Prof.Dr.</investigator_title>
  </responsible_party>
  <keyword>Risperidone</keyword>
  <keyword>Therapeutic Drug Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

